Tumor Associated Macrophages

Image

Macrophages (green) are shown attaching to a metastatic tumor cell (blue) in the lung — a process that promotes metastatic growth. (Credit: Albert Einstein College of Medicine)

Metastasis appears to rely on macrophages, immune cells that usually defend against disease.  A recent study done at Albert Einstein College of Medicine of Yeshiva University found a distinct population of macrophages that helps malignant cells set up shop at distant sites, as well as a target for drug therapy, showing that killing these macrophages greatly reduces the metastatic tumor.  

Macrophages are associated with the development and progression of a variety of tumors, including breast, prostate, glioma, lymphoma, bladder, lung, cervical and melanoma.  In breast cancer, macrophages have been reported to comprise up to 50% of the tumor cell mass. High levels of macrophages are correlated with increased metastasis and poor prognosis.  Tumor-associated macrophages (TAMs) are thought to acquire an M2 (wound healing/regulatory state) phenotype, contributing to cell survival, proliferation, and dissemination.  

Macrophages are attracted to hypoxic environments and necrotic tumor cells. The intense cross-talk between macrophages and neoplastic cells allows for the continuous process of matrix deposition and remodeling, which facilitates tumor growth and invasion of the surrounding tissues.  Macrophages promote chronic inflammation by releasing inflammatory compounds like Tumor Necrosis Factor-alpha which activates the gene switch TNF-kB.  Once TNF-kB is turned on, it enters the nucleus of a tumor cell and turns on proteins that stop apoptosis, promoting proliferation and extending inflammation.  

Macrophages also promote angiogenesis by releasing VEGF, TNF-alpha, granulocyte macrophage colony-stimulateing factor (GM-CSF), IL-1 and IL-6.  They also secrete the angiogenic factor thymidine phosphorylase, which promotes endothelial cell migration as well as several angiogenesis modulating enzymes such as MMP-2, MMP-7, MMP-9, MMP-12, and cyclooxygenase-2.

On the other hand, some investigations showed that the TAMs might play an important role in anti-tumor activity. The possible anti-tumor function of TAMs may be through enhancing MIF nuclear translocation, GM-CSF, and IL-12 expression. Differentiation of TAMs to a cytotoxic macrophge subpopulation may also contribute to the antitumor function of TAMs.

Image

 

Sources:

http://www.sciencedaily.com/releases/2009/08/090810174303.htm

http://www.jleukbio.org/content/86/5/1065.full.pdf+html

http://www.medscape.com/viewarticle/734992

Click to access JOCM%202(3)%20101-106.pdf

VEGF and Angiogenesis

The diffusion of oxygen through tissues is limited to 100-200 micrometers, therefore as tumors grow, they need angiogenesis in order to gain malignancy and increase in size.  Once a tumor becomes vascular it is said to have undergone a “angiogenic switch” where dormant avascularized hyperplasia progresses to an outgrowing vascularized tumor and then eventually to malignant tumor progression.  The blood vessels formed by angiogenesis are highly disorganized and leaky (openings in walls).  The tumor vessels are not able to mature through the recruitment of smooth muscle cells and pericytes.  This phenomenon was crucial in the discovery of VEGF.

nrc1093-f2

An important tumor suppressor gene involved in anti-angiogenesis is p53, which arrests cell cycle progression under nonviable conditions and mediates hypoxia-induced apoptosis.  p53’s gene products promote the expression of thrombospondin and inhibit the expression of  VEGF-A.  The loss of p53 function enhances the heterodimerization of HIF-1 alpha with HIF-1beta and up-regulates the expression of VEGF-A in tumor cells. Angiogenesis will occur because there is a net balance of activators over inhibitors.

VEGF receptors are expressed on endothelial but few other cells.  They stimulate proliferation, migration, survival, and secretion of matrix-degrading enzymes.  VEGF is secreted from the tumor and binds to signal receptors on the endothelial cells of existing blood vessels, leading to the formation of new blood vessels, extending tumor cell survival and growth.

slide003

VEGF-A has been shown to modulate the production and activity of matrix metalloproteases (MMPs).  MMPs break down the extra-cellular matrix, one of the earliest stages in the development of angiogenesis.

VEGF-A upregulates the expression of Bcl-2 (anti-apoptotic protein) which enhances endothelial cell survival and reduces the risk for apoptosis.  Bcl-2 acts by preserving the mitochondrial integrity.

VEGF-A upregulates survivin, which also inhibits apoptosis by suppressing caspase activity.

VEGF-A may function as a positive feedback regulator during platelet activation.  Platelets cover tumor cells, offering protection from cytolysis by natural killercells.  Tumor cell platelet aggregates can lodge in circulation, adhering to the vascular endothelium, and fascilitate tumor cell aggregation.

VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor.

Isoforms of the p63 gene, TAp64 and dNp63 bind to the VEGF promoter region and regulate the expression of the VEGF gene.  The expression of the VEGF gene is correlated with these isoforms and their regulation HIF-1 stability: the degredaiton of HIF-1 is stimulated by TAp63, and dNp63 stablizes it.

Inhibiting VEGF in cancer therapy

Bevacizumab (Avastin®)  was the first angiogenesis inhibitor shown to decrease tumor growth.  It is used alone with glioblastoma and in combination with colorectal cancers, some small-cell lung tumors and with metastatic renal cell cancer.  Bevacizumab traps VEGF in the blood, lowering its concentration and inhibiting new blood vessel formation.

sorafenib (Nexavar®)- hepatocellular carcinoma and kidney cancer

sunitinib (Sutent®), everolimus(Afinitor®)- kidney cancer and neuroendocrine tumors

pazopanib (Votrient®)- kidney cancer

Angiogenesis inhibitors are an important tool in future cancer treatment.  According to the NCI, there are many drugs that are currently in Phase III Trials, showing a promising future for treating cancer by inhibiting blood supply.

Types of Cancer in Active Phase III Treatment Clinical Trials of Angiogenesis Inhibitors:

Angiogenesis inhibitors are also being used to treat some diseases that involve the development of abnormal blood vessel growth  such as macular degeneration.  They are also currently being investigated as an anti-obesity agent as blood vessels in the adipose tissue never fully mature, and are destroyed by angiogenesis inhibitors.

 

Inhibiting angiogenesis can also be controlled in the diet.  To prevent metastasis, the cancer patient should increase the following foods in their diet:

  • soy products such as tofu and tempeh
  • Agaricus blazei, Reishi, Trametes versicolor, Ganoderma lucidum, and Phellinus linteus mushrooms
  • Black raspberry extract
  • Green Tea
  • Liquorice
  • Red Wine
  • Royal Jelly

Sources:

http://pharmrev.aspetjournals.org/content/56/4/549.full.pdf+html

http://www.sciencedirect.com/science/article/pii/S1044579X09000649

“VEGF and Angiogenesis” Einstein Quart. J. Biol. and Med. (2001) 18:59-66

http://en.wikipedia.org/wiki/Angiogenesis_inhibitor#cite_note-18

BRCA1 & BRCA2: Breast Cancer and Gene Patents

BRCA1 and BRCA2 (BReast CAncer susceptibility 1 and 2) are tumor suppressor genes that help to ensure the stability of cell’s genetic material and also help prevent uncontrolled cell growth.  Everyone has these genes, and when they are mutated and passed from generation to generation, they don’t function normally, resulting in an increase risk of breast cancer of up to 80%.  Abnormal BRCA1 and BRCA2 genes may account for up to 10% of all breast cancers and persons with these genes have a family history of breast and ovarian cancer.  These women also have an increased risk of developing colon, pancreatic, and thyroid cancers, as well as melanoma.  However, because genetics play only a 5-10% role in all breast cancers, most people who develop breast cancer did not inherit an abnormal breast cancer gene and have no family history of the disease.  The likelihood of a child inheriting the BRCA1/2 mutated genes if one parent that has the mutation is 50%.  However the likelihood of developing cancer depends on penetrance of the mutation and age and gender of the individual.

Mutations in males also increase the risk for breast cancer, pancreatic cancer, and prostate cancer, but they appear to be more strongly associated with BRCA2 gene mutation.

Pathophysiology: 

BRCA1 and BRCA2 are genes located on chromosome 17q21 and 13q12-13 respectively.  Carcinogenesis is often initiated by repeated episodes of DNA damage, which can occur due to a number of stressors such as reactive oxygen species, cytotoxic chemotherapy, and ionizing radiation.   DNA double-strand breaks are particularly harmful because both complementary strands of DNA are damaged, leading to replication arrest. BRCA1 and BRCA2 play a role in the response to cellular stress, the localization to sites of damaged DNA, and the activation of DNA repair processes.  BRCA2 is primarily involved in homologous recombination repair and BRCA1 is involved in alternate DNA repair processes such as nonhomologous end joining.  BRCA1 interacts with RAD51, which assists in homologous repair of the double-stranded DNA breaks. The loss of functional BRCA1 or BRCA2 leads to activation of p53, causing cell cycle arrest or apoptosis.  If p53 is inactivated, proliferation results in progressive accumulation of DNA damage and increased frequency of malignancy.  As a result of the failure of cells to arrest and repair DNA damage or to self-destruct, a BRCA mutation ultimately leads to the accumulation of genetic mutations, resulting in neoplastic progression.

Image

 

Genetic Testing and gene patents:

BRCA1 and BRCA2 gene mutations are inherited in an autosomal dominant fashion.  There are several methods to test for BRCA1 and BRCA2, with most methods looking for changes in DNA.  One method looks for proteins produced by these genes, but frequently a combination of methods is used in addition to genetic counseling.  

Myriad Genetics along with the University of Utah, isolated BRCA1 and BRCA2 and developed BRACAnalysis®, a test costing more than $3,000, that searches extracted DNA for mutations that indicate a woman is at a high risk of getting breast or ovarian cancer. The patent on the genes prevents other laboratories from performing similar tests.  The test was launched in the US in 1996.  In 1997, the first BRCA1 patent was granted in the U.S. to the University of Utah, NIEHS and Myriad Genetics, and in 1998, the first BRCA2 patent was also granted. 

Gene patenting is a recent popular debate about whether or not patenting genes is against the patent law stating that you are not allowed to patent naturally occurring things.   Myriad Genetics was recently a defendant in a lawsuit, Association for Molecular Pathology vs Myriad Genetics, regarding their BRCA1 and BRCA2 patents.  On March 29, 2010, two of the company’s patents on the BRCA1 and BRCA2 genes were ruled invalid, and then after appeal, patents were reinstated in July of 2011.  There was yet another appeal, and The Supreme Court ruled in the latter case but required more restrictive rules to patent observations about natural phenomena.  There is an appeal for a re-review for The Supreme Court but the result isnt said to be made until June 2013.

For more information see: 

  1. ACLU appeals Myriad Genetics gene patent case to Supreme Court
  2. Myriad’s Human-Gene Patent Rehearing Ordered by Supreme Court
  3. Myriad Genetics wins ability to patent isolated DNA
  4. Supreme Court Invalidates Prometheus Diagnostic Patents
  5. Prometheus Decision a Harbinger for Myriad?

 

 

Sources:

http://www.ncbi.nlm.nih.gov/books/NBK1247/

HPV and Cancer

A few years ago, my friend told me about a health aid program in Detroit that allowed women 25 and under to receive Gardasil shots for $8 each (3 shots total over 6 months).  In women ages 9 to 26, the Gardasil vaccine helps protect against 2 types of HPV that cause about 75% of cervical cancer cases, and 2 more types that cause 90% of genital warts cases.  At the time, I was 25 and had only associated HPV with genital warts.  Being excessively terrified of STD’s (as an all girl catholic high school education can exasturbate), I took advantage of it right away and received 3 gardasil shots, totaling $24.  Well, it turns out my friend did me a huge favor.  Gardasil runs full price for about $120 for each shot ($360 total), well worth the HPV types 6, 11, 16, and 18 it protects you from.  Since this is a blog about cancer, ill concentrate on types 16 and 18, known to cause about 70% of vaginal cancer and up to 50% of the cases of vulvar cancer.  Types 6 and 11 are associated with genital warts.

There are about 120 types of the Human papillomavirus (~40 sexually transmitted) that, like all papillomavirus’, infect the keratinocytes of the skin or mucous membranes.  Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 are carcinogenic sexually transmitted HPV’s and may lead to the development of cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), penile intraepithelial neoplasia (PIN), and/or anal intraepithelial neoplasia (AIN).

Image

HPV types 16 and 18 account for 99.7% of all cervical cancers.  Type 16 has also been associated with oropharyngeal cancer.  A study done by The California Dental Hygienists’ Association in 2011 predicted that HPV will replace tobacco as the main causative agent for oral cancer.  This may be due to the fact that the mouth is very similar to the vagina and cervix on a cellular level.  Both organs have the same type of epithelial cells that HPV 16 and HPV 18 target.

Image

The HPV virus has eight genes that are categorized as being either: E denoting ‘early’ or L meaning ‘late’.  E1 and E2 are involved in viral genome replication and transcription control, E5 enhances the activity of epidermal growth factor, and E6 and E7 interfere with the host cell’s control of transcription and the cell cycle.  L1 and L2 encode viral capsid proteins used in the construction of new viruses.

Two genes that play an important role in HPV and carcinogenesis are E6 and E7, which act as oncogenes that promote tumor growth and malignant transformation by inactivating two tumor supressor genes, p53 and pRb. E6 is associated with the cellular protein E6-AP, which is involved in the ubiquitin ligase pathway that degrades proteins by binding ubiquitin to the p53 protein, flagging it for proteosomal degradation (this accounts for the very low levels of p53 in cervical carcinoma cell lines).  In the presence of DNA damage, the p53 protein prevents cell growth and stimulates apoptosis.  It also upregulates the p21 protein, blocking the formation of the Cyclin D/Cdk4 complex, preventing the phosphorylation of Rb and halting cell cycle progression by preventing the activation of E2F, a transcription factor that causes cell cycle progression. When p53 is degraded, there is no apoptosis and viral DNA replicates.

E7 is a transforming protein that binds to the retinoblastoma tumour suppressor gene product pRb, with a preference for active and unphosphorylated pRb.  High-risk E7 proteins (in HPV 16 and 18) have an approximately ten-fold higher affinity for pRb protein than the low risk HPV E7 proteins.  When E2F is bound to Rb, it cannot act as a transcription factor and cannot cause the cell to divide. But, if E7 binds to Rb, E2F is then free to act as a transcription factor, causing the cell to divide, a critical step in cancer development.

The degree to which E6 and E7 are expressed is correlated with the type of cervical lesion that can ultimately develop.

Image

Image

Most HPV infections in young females have no long-term significance, with nearly 90% gone in two years, but if the infection persists, the risk for cervical cancer increases.  The progression of HPV infection to cervical cancer can takes a long time (10-15 years), so detection of cervical cancer is usually seen in older women who were exposed to HPV when they were young.  Because prevention to carcinogenesis is key, a Pap smear is recommended, which is used to detect abnormal cells on the cervix.  If they are found, a colposcopy follows where biopsies are taken and abnormal cells can be removed.

Having the Gardasil vaccine does not prevent me from an HPV infection, or lets face it, STD’s, but it is comforting to know that were trying and that science is staying on par with viruses and how they effect women (and men) in the future.  The war on cancer still persists, and Gardasil is an important step in fighting cancer and viruses that increase the risk for cancer.  I only wish the public could be more educated of opportunities like Gardasil, and that the health department continue to keep prices low so that all people have an equal opportunity to decrease their risk of cervical cancer and  of corse, genital warts.

Sources:

http://www.oralcancerfoundation.org/facts/humanpapillomavirus.htm

http://www.gardasil.com/hpv/human-papillomavirus/index.html

http://cancerres.aacrjournals.org/content/62/23/7075.full

http://www.microbiologybytes.com/virology/Papillomaviruses.html

http://www.cancerquest.org/how-hpv-causes-cancer.html

http://en.wikipedia.org/wiki/Human_papillomavirus

23andMe

You are you because of your genome: 3.2 billion base pairs that control every physical trait, including any SNPs that predispose you to certain cancers.  What if you knew your genome and your predispositions?

23andMe is a DNA analysis service, where for $99, a saliva sample is mailed to a lab where 960.000 of the genomes SNPs are analyzed, using the Illumina OmniExpress Plus Genotyping BeadChip, and compared to other genomes to show an increased or decreased risk for disease, carrier status, drug response, certain traits, and genealogy.

Due to increased investments totaling over $100 million, the price has been reduced dramatically, from $999 in 2007, in order to increase the customer base from 180,000 to 1 million.  Investors include Google co-founder Sergey Brin (married to 23andme co-founder  Anne Wojcicki), Yuri Milner, New Enterprise Associates, MPM Capital, and Google Ventures.  Aside from being Wojicicki’s husband, another reason Brin would invest in 23andme is that Google is a huge search engine and 23andme could could help maintain a market by  indexing another aspect of the world’s information, including an increased market in health care and biotechnology.

43968v1-max-450x450

 

Sources:

https://www.23andme.com/

Another $50M Richer, 23andMe Drops Its Price To $99 Permanently. But Will The Average Dude Buy In?

The FTO Gene and Malignant Melanoma

Overactivity of the FTO gene is often associated with obesity, encoding for the Fat mass and obesity-associated protein, in Intron 1, leading to overeating and an increased Body Mass Index.  People with high BMI’s are at risk for kidney diseases, type 2 diabetes, endometrial cancer and a lot of other illnesses. As of recently, it has been shown that the FTO gene also has a link to malignant melanoma, found in Intron 8, a disease not associated with obesity and high BMIs.

These results were found by at the University of Leeds as part of the Melanoma Genetics Consortium using a case-control study where the researchers analyzed the genomes of people who developed melanoma, and the genomes of people without it.   They wanted to determine whether changes in single-nucleotide polymorphisms (SNPs) were present more frequently in people with melanoma.  They adjusted the BMI regions of the FTO gene to rule out the possibility that obesity contributes to the development of melanoma.  They also looked to see if the SNPs associated with melanoma were also associated with melanoma in another group of cases and controls.

They analyzed SNPs from people of European origin in 1,353 people with melanoma and 3,566 people without melanoma, then replicated their findings in 12,314 people with melanoma and 55,667 people without melanoma from Europe, Australia and the US who had European ancestry.

The researchers initially identified three SNPs in the FTO gene that were significantly associated with melanoma.  One SNP (rs16953002) was associated with 32% increased odds of melanoma.  The association between rs16953002 and melanoma existed even after BMI was adjusted for.  This was the first study to identify and replicate an association with SNPs in FTO not related to BMI.

Dr Julie Sharp, Cancer Research UK’s senior science information manager, said: “These are fascinating early findings that, if confirmed in further research, could potentially provide new targets for the development of drugs to treat melanoma.  Advances in understanding more about the molecules driving skin cancer have already enabled us to develop important new skin cancer drugs that will make a real difference for patients.”

Melanoma is malignancy effecting the melanocytes, and is the leading cause of death in skin cancer (75%).  Melanoma can originate in any part of the body containing melanocytes: bottom layer of epidermis, inner ear, meninges, bones, bowel and heart.  An increased geographic pattern of incidence is associated with UV light exposure crossed with the amount of skin pigmentation in the population.ImageImage

 

 

Sources:

Glynn, Sarah. “Obesity Gene Linked to Skin Cancer.”  Medical News Today. 05 March, 2013

Soos, Andy.  “Melanoma and Obesity Connection.” Environmental News Network. 07 MArch 2013

http://www.nhs.uk/news/2013/03March/Pages/Skin-cancer-obesity-genetic-link.aspx

http://www.bbc.co.uk/news/health-21635696

http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.2571.html

Genes and Cancer: Oncogenes and Tumor Suppressor Genes

The two main types of genes that are associated with cancer are oncogenes and tumor suppressor genes.  Oncogenes are MUTATIONs of proto-oncogenes that lead cells to tumorgenesis WHEN there is also an ELIMINATION of tumor suppressor genes.  Tumor suppressor genes protect the cell from oncogenes, so when they are eliminated, uncontrolled cell proliferation and therefore tumorgenesis occurs.

ONCOGENES

Proto-oncogenes are wild type (normal) genes that code for proteins regulating cell growth and differentiaition. When altered by mutation or overly expressed, they can become an oncogene, a cancer causing gene.

Examples of proto-oncogenes are:

RAS: a G protein that acts as binary signaling switch (“on or “off”) that controls intracellular signaling networks (proliferation, differentiation, adhesion, apoptosis, migration).

MYC: gene that encodes for a multifunctional protein that regulates transcription of specific target genes and also plays a role in cell cycleprogression, apoptosis and cellular transformation.

SRC: encodes for tyrosine kinase that plays role in regulation of embryonic development and cell growth.

WNT: network of proteins in a signaling pathway that passes signals from receptors to the nucleus to express target genes, also controls cell-to-cell communication between embryo and mother.

ERK: intracellular signaling protein kinases that are involved in the regulation of cell division and differentiation.

TRK: Tyrosine kinases that are specific in regulating nerve growth.

Proto-oncogenes can be converted (activated) to oncogenes in 3 basic ways:

1.  Mutation

Base substitutions, deletions, insertions and other various types of mutations can activate the proto-oncogene, leading to uncontrolled activity of the mutated protein and a loss of regulation.  In human tumors, most oncogene mutations are base substitutions (point mutations) that change a single amino acid within the protein.

Ras mutation is a common example: K-ras mutations are found in 30% of lung adenocarcinomas, 50% of colon carcinomas, and 90% of carcinomas of the pancreas. N-ras mutations are commonly found in hematologic malignancies, with up to a 25% incidence in acute myeloid leukemias and myelodysplastic syndromes.

LARGE_428_2008_665_Fig2_HTML-1

LARGE_428_2008_665_Fig2_HTML-1

Oncogenic mutations in ras genes prevent the protein from hydrolyzing GTP to GDP. As a result, the protein remains always in its active GTP-bound form, continually activating the MAP kinase cascade, leading to proliferation.

Oncogenic mutations in ras genes prevent the protein from hydrolyzing GTP to GDP. As a result, the protein remains always in its active GTP-bound form, continually activating the MAP kinase cascade, leading to proliferation.

2.  Gene Amplification

The normal DNA processes is flawed resulting in many copies of the genes that are located on a region of a chromosome.   If an oncogene is included in the amplified region, the resulting overexpression of that gene can lead to deregulated cell growth.  Sometimes, so many copies of the amplified region are produced that they can actually form their own small pseudo-chromosomes called a double-minute chromosome (DM). A homogeneously staining region (HSR) can also form,  amplifying a segment of a gene  that has selective advantage for cancer, that stains flourescent over the entire amplified region.  Examples include: the amplification of the myc oncogene in a wide range of tumors and the amplification of the ErbB-2 or HER-2/neu oncogene in breast and ovarian cancers.

Metaphase FISH analysis of the apocrine carcinoma showing amplification of the HER-2/neu gene (red). One of the larger marker chromosomes contains homogeneously staining region (hsr) of HER-2/neu gene amplification.

Metaphase FISH analysis of the apocrine carcinoma showing amplification of the HER-2/neu gene (red). One of the larger marker chromosomes contains homogeneously staining region (hsr) of HER-2/neu gene amplification.

3.  Chromosomal Rearrangements

These rearrangements consist mainly of chromosomal translocations and, less frequently, chromosomal inversion.  Chromosomal translocations involve breaking and rearrangement of chromosomal fragments.  They can occur by relocating a proto-oncogene to a new chromosomal site or by fusing a proto-oncogene and a second gene together.  These genes may not be transcribed or translated appropriately and can increase, decrease, or turn off transcription.  Translocations are common in lymphomas and leukemuias, for example, the exchange between chromosomes 9 and 22 that is in over 90% of patients with chronic myelogenous leukemia.  The translocation leads to a shortened chromosome 22 and the formation of an oncogene from the abl proto-oncogene.

In Chromosomal Inversions, segments of DNA are released and are reinserted in the opposite orientation.  This rearrangement can either activate an oncogene or deactivate a tumor suppressor gene.

TUMOR SUPPRESSOR GENES

Tumor Suppressor genes code for proteins that: suppress the activity of oncogenes by protecting the genome from mutagenic events, impeding on dysregulated progression through the cell cycle, inducing apoptosis in cells that escape normal cell cycle controls, and inhibiting cellular migration and metastasis. The elimination of tumor suppressor genes allows oncogenes to cause cells that should have died, to proliferate instead.  The elimination of tumor suppressor genes occurs via a “Two-Hit Hypothesis” which states that both alleles need to be eliminated or unactivated, possessing a double recessive allele.  If only one allele is damaged, the second can still produce the correct protein.  An example of how this mechanism works can be seen in an experiment with retinoblastoma.

There are two types of retinoblastomas: Sporadic (Unilateral) and Familial (Bilateral).  The Rb gene is a tumor-supressor gene that prevents cell growth by inhibiting cell cycle progression until the cell is ready to divide.  In Familial Retinoblastoma, one mutation is inherited along with a normal Rb allele and the second mutation occurs in somatic cells.   After the second mutation in the other Rb gene, all pRb in that cell would be ineffective at inhibiting cell cycle progression, allowing cells to divide uncontrollably and eventually become cancerous.  Because one allele is already mutated in all other somatic cells, these individuals are 6 times more likely to develop other types of cancer later in life.  In Sporadic Retinoblastoma, two different mutations on the Rb gene occur somatically, and therefore require more time and a lesser incidence of acquiring future types of cancer.

10.1038_35101031-f3_full

Because tumor suppressor genes need to lose both copies of the allele (recessive), having one copy of the normal gene is still a normal functioning gene (heterozygous).  In order for a tumor supressor gene to become cancerous it has to undergo a loss of heterozygosity (LOH).  LOS can occur through: deletion or inactivation of normal allele or chromosome, loss of normal gene followed by duplication of mutant gene, or mitotic recombination.

Tumor suppressor genes can also be blocked by hypermethylation of their promoter. The promoter region is a cytosine-guanine rich region of the transcription site, and methylation occurs when these bases are located in a position that is 5′ to guanosines in the sequence CpG.  Methylation of this site results in the silencing of that gene by turning off transcription.  When methylated CdGs and histone deacetylase are bound to DNA, the histone deacetylase removes acetate groups that are attached to amino acid residues of histones in the nearby chromatin.  The deacylation of the histones converts the chromatin to a strange configuration, blocking transcription.  During the DNA replication S phase, maintenance methylases attach methyl groups to newly sequenced CpGs, and therefore pass promoter methylation onto daughter cells.  To inactivate the tumor suppressor gene, both alleles can be methylated independently OR one copy is lost due to methylation and the other through LOH accompanied by a duplication of the methylated TSG copy.

1-s2.0-S0959804909000070-gr2

CpG island hypermethylation is commonly found in  hematologic malignancies such as leukemia or lymphoma.

1-s2.0-S1521661603002080-gr1

An important class of TSG’s that is different  in that they  do not regulate cell division are called Stability genes.  Stability genes (aka gatekeeper genes) are involved in recognising and repairing DNA damage.  Inactivation of stability genes causes genetic instability due to a lack of repair mechanisms, leading to an increase in the mutation rate of ALL genes, including oncogenes and tumour suppressor genes.  Stability genes include mismatch repair genes (MMR), nucleotide-excision repair genes (NER) and base-excision repair genes (BER), that are responsible for repairing subtle mistakes made during normal DNA replication or other mutations.  Stability genes can also involve large portions of chromosomes, such as mitotic recombination and chromosomal segregation.

 

Sources:

Weinberg, Robert A (2007). The Biology of Cancer. Garland Science.

Kinzler, K and Volgstein, B (2004). “Cancer Genes and the Pathways They Control.” http://www.nature.com

http://www.cancerquest.org/gene-amplification.html

http://www.nature.com/modpathol/journal/v23/n5/fig_tab/modpathol201050f3.html

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC389051/

http://www.nature.com/scitable/content/one-hit-and-two-hit-curves-for-48093

http://www.ncbi.nlm.nih.gov/pubmed/12154405

New Drug Approved for Breast Cancer

On February 22, 2013, the FDA Approved a new drug, Kadcyla, which is used to treat patients with HER-2 positive metastatic breast cancer.  This drug is different than the usual breast cancer drugs because it not only targets cancer cells, it spares healthy ones.  Kadcyla combines Herceptin with other chemotherapy drugs and keeps them intact until it reaches the tumor to kill cancer cells.  The drug is only approved for patients who had little progress taking Herceptin and/or taxane, which are both used in the treatment of breast cancer.  In clinical trials, this drug delayed  progression of cancer by several months compared to lapatinib plus capecitabine therapy. The median overall survival was 30.9 months in the Kadcyla group and 25.1 months in the lapatinib plus capecitabine group.  The price for Kadcyla is currently  $9,800/month compared to the price of Herceptin at $4,500/month.

HER-2 is an oncogene expressed in 20% of breast cancer cases and is usually a more aggressive type of cancer. When the ERBB2 oncogene is amplified, it greatly increases the expression of HER-2 on tumor breast cells which transforms them into a malignant phenotype, accelerating tumorigenesis.

Image

Article :http://www.huffingtonpost.com/2013/02/22/fda-approves-new-breast-cancer-drug-kadcyla_n_2742241.html

FDA: http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194949.htm

HER-2 source: http://www.molecularonc.com/mor/mor010106.html

Join the Fight Denver!

denver-skyline-taken

I work for a wonderful couple, Frank and Jacqueline Bonanno, who own Bonanno Concepts, operating 10 restaurants in Denver. Yesterday, some of the Bonanno restaurants donated part of proceeds to an old Chef, Drew Inman, who was diagnosed with terminal lung cancer at the age of 41. The proceeds go to pay for his medical bills and also to the Lung Cancer Alliance. Its these small acts of kindness and the participation of the community that help fund cancer awareness and treatment. They improve the quality of life of cancer patients and so the overall quality of the world. Helping where you can always makes a difference.

The Lung Cancer Alliance is a non-profit organization dedicated solely to providing support and advocacy for people living with or at risk for the disease.(http://www.lungcanceralliance.org/)

Other things in Denver to help the fight against cancer:

Jodis Race, Ovarian Cancer Alliance 5K: June 1, 2013 http://www.colo-ovariancancer.org/jodisraceforawareness
Undy Alliance, Colon Cancer Alliance: June 22, 2013 http://support.ccalliance.org/site/PageServer?pagename=undy_landing
Crawl for Cancer: August 17, 2013 http://www.crawlforcancer.org/denver
Romp to Stomp, Snowshoe Series: March 2, 2013 http://www.komendenver.org/
Race for the Cure: September 29,2013 http://www.komendenver.org/
Pink Tie Affair: November 9,2012 http://www.komendenver.org/
Race for Research 5K at Wash Park: August 18, 2013 http://cancerleague.org/
Hope Ball-Dedicated to the ones we love: May 4, 2013 http://cancerleague.org/
Cure Search Walk for Childrens Cancer: August 10, 2013 http://www.curesearchwalk.org/
Light the Night Walks: September 21 (Boulder) September 26 (Wash Park, Denver), 2013 http://www.lightthenight.org

Warrior pink clothing: http://www.warriorsinpink.ford.com/be-a-warrior/